demonstrate that the transient reduction of TDP-43 using gapmer-type antisense oligonucleotides suppresses cytoplasmic TDP-43 aggregation and disease phenotypes in vivo, indicating the therapeutic potential of the TDP-43-lowering approach for ALS/FTD treatment. Here, TARDBP is linked to amyotrophic lateral sclerosis.